Cogent Biosciences heads into its August 13 earnings report with options traders at their most bullish in a year and a meaningful short position that has started to retreat — a setup that makes the print feel secondary to the November FDA decision looming over everything.
The options signal is the sharpest data point this week. Call positioning has surged to an extreme, with the put/call ratio at 0.226 — almost exactly at its 52-week low of 0.225, and more than two standard deviations below its 20-day average of 0.27. That is not routine bullishness; it is an options market priced for upside, almost certainly anchored to the November 30 PDUFA date for bezuclastinib in gastrointestinal stromal tumors. The PCR had been drifting lower for weeks before breaking to this low on August 6-7, suggesting fresh call buying rather than simple decay of puts.
Short positioning tells a more complicated story, and the contrast is worth naming explicitly. At 10.2% of the free float — roughly 15.5 million shares — this is a genuinely elevated short base for a name with a hard regulatory catalyst on the calendar. Short interest has climbed about 5.7% over the past month and ticked up again this week, even as the stock gained nearly 9%. Yet the borrow market is relaxed. Availability runs at 830% — meaning there are roughly eight shares available to borrow for every one currently lent out — and cost to borrow is just 0.58%, near its lowest level of the past six months despite a 47% rise over the month. Shorts are rebuilding, but they face no squeeze pressure in the lending pool whatsoever. The short score of 55.4 sits in the lower half of its recent range after pulling back from 57.7 earlier in the week.
The Street has settled into a uniformly positive posture. All eight analysts tracked carry buy-equivalent ratings, with consensus targets clustered around $55 — roughly 30% above the current $42.39. Jefferies initiated at Buy with a $55 target in March, and coverage has not wavered since. The bull case rests squarely on the FDA priority review and Phase 3 data in GIST, with analysts citing a potential $9.4 billion addressable market. The bear case is narrower: clinical execution risk and the possibility of commercial underperformance if approval materialises. Valuation multiples are negative across the board — this is a pre-revenue biotech — with price-to-book the only conventional anchor at 21x, up about 4% over the past month as the stock has crept higher. Factor scores are mixed: EPS surprise ranks at the 70th percentile, reflecting estimate beats on a loss-per-share basis, while the short score ranks at just the 31st percentile, consistent with the elevated but not extreme SI reading.
The earnings history adds a note of caution to the bullish options tilt. Three of the last four quarterly prints produced negative next-day moves, ranging from -1.4% to -5.9%, with five-day moves consistently negative in those same instances. The sole positive print — a 0.7% gain on June 9 — extended to a 6.1% gain over the following week, suggesting that when COGT does catch a bid post-earnings, it tends to follow through. With the stock up nearly 9% on the week ahead of the August 13 report, the implied bar for the print is set meaningfully higher than it was a month ago.
What to watch: whether the August 13 earnings call provides any updated language on bezuclastinib's commercial readiness or trial enrollment cadence — those details, rather than the quarterly loss figure itself, will determine how the November PDUFA date gets priced into the remaining months of the year.
See the live data behind this article on ORTEX.
Open COGT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
